Abstract: The present invention is directed to methods for extracting markers from biological samples, and to systems, devices, kits and reagents for use in such methods. The invention is also to methods, kits, reagents and compositions for measuring a plurality of different organism types in a sample. One of the specific advantages of the present invention is the ability to simultaneously extract more than one microorganism or viral particle marker in one volume from a single sample containing a complex biological matrix.

Abstract: A simple, biocompatible system and procedure for generating nitric oxide (NO) is described. A mixture of powdered sodium nitrite, ascorbic acid, and maleic acid (or another organic acid of adequate strength) immediately generates nitric oxide (NO) on treatment with water. To slow down the NO generation, one may prepare an ointment from a nonaqueous medium (petrolatum, Vaseline™) and the three powdered ingredients, which on being applied topically on the skin will release NO as water permeates through this medium; alternatively, one may convert the aqueous sodium nitrite solution into a gel with hydroxyethylcellulose (or other gel-forming compound) and combine this gel with another gel obtained from aqueous ascorbic and maleic acids with hydroxyethylcellulose for topical application (on intact skin, burns intra-cavity, burns, intra-cavity, etc.).

Abstract: Pulmonary disorders in which the GSNO pool or glutathione pool in the lung is depleted and where reactive oxygen species in lung are increased, are treated by delivering into the lung as a gas, agent causing repletion or increase of the GSNO pool or protection against toxicity and does so independently of reaction with oxygen. Agents include ethyl nitrite, NOCl, NOBr, NOF, NOCN, N2O3, HNO, and H2S. Optionally, N-acetylcysteine, ascorbate, H2S or HNO is administered in addition to other GSNO repleting agent to potentiate the effect of said agent.

Abstract: A surgical irrigating fluid composition, especially for endoscopic surgery, is provided comprising a rinsing fluid and nitrous oxide added as a marker to the rinsing fluid in an amount which is detectable in the expired breath from a mammal, especially man, that is subjected to the surgery.

Abstract: Inhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. Precise delivery of nitric oxide at therapeutic levels of 20 to 100 ppm and inhibition of reaction of nitric oxide with oxygen to form toxic impurities such as nitrogen dioxide can provide effective inhalation therapy for pulmonary hypertension.

Abstract: A method of treating animal manure solids comprises contacting the solids with a treatment composition comprising AlCl3.nH2O or Al(NO3)3.mH2O, or the residue of AlCl3.nH2O or Al(NO3)3.mH2O, to form a treated waste product, wherein n is from 0 to 10, and m is from 0 to 12. The treatment amount can be effective to reduce phosphorus solubility in the manure; reduce phosphorus runoff and/or phosphorus leaching from fields fertilized with manure; inhibit ammonia volatilization from the manure; flocculate solids in the manure; reduce pathogens in the manure; increase the nitrogen content in the manure; and/or reduce acid rain and PM-10s associated with the manure.

Abstract: A mold inhibitor integrated within a matrix and a method of making the same are disclosed. The matrix is preferably made of a processed sorghum grain, and preferably from hybrids of Milo. The grain is subjected to decortication and extrusion. Agents are added to the decorticated Milo prior to extrusion. The agents may be anti-fungal agents or anti-microbial agents. In use, the produced matrix is spread and placed upon a targeted area which requires either remediation or prevention of growth of fungus or microbes.

Abstract: Biocompatible metallic medical devices having silanized surfaces coupled to nucleophile residues that release sustained, therapeutic amounts of nitric oxide to specific sites within a mammalian body are provided. Additionally, the biocompatible metallic medical devices can also be provided with anti-thrombogenic, lubricious coatings that release sustained, therapeutic amounts of nitric oxide. Moreover, the silanized metallic devices are surprisingly durable when exposed to harsh chemical methods often needed to bind nitric oxide-releasing functional groups to nucleophile residues. Furthermore, methods are provided for producing stable, silanized, sustained nitric oxide-releasing metallic medical devices.

Abstract: A highly acidic metalated organic acid composition and its preparation. The acidic composition can be prepared by mixing a monovalent or polyvalent cation and an organic acid in the presence of a strong oxyacid, wherein the resultant acidic composition is less corrosive to a ferrous metal than a solution of a mineral acid having the same acidic pH value as that of the acidic composition, and where in the acid composition is more biocidal than a mixture of the organic acid and a metal salt of the organic acid which mixture has the same acid normality value as that of the acidic composition. The acidic composition can be prepared by mixing at least one regenerating acid, at least one metal base, and at least one organic acid, wherein the amount of the regenerating acid is in excess of the equivalent amount of the metal base.

Abstract: Disclosed is both a method and composition for controlling deleterious organisms, such as insects, nematodes and weeds by applying a compound comprised of a liquid medium comprising an azide and an azide stabilizer. The azide can be selected from the group consisting of sodium azide and potassium azide or a combination of the two. The composition provides an effective pesticide, without causing significant harm to the environment. The composition may be applied to soil to control a population of a deleterious organism.

Abstract: Biocompatible polymeric materials capable of providing in situ release of nitric oxide (NO) included diazeniumdiolated fumed silica as a filler in a multilayer polymer structure to release NO upon contact with water (blood). The blood-contacting polymer surface is preferably multi-layered so that the NO-releasing layer, containing the diazeniumdiolated fumed silica, is shielded from blood contact by one or more top (or base) coats. When in contact with blood, the NO released at the surface of the polymer prevents platelet activation and adhesion to the surface, thereby reducing platelet consumption, risk of thrombus formation and other clinical complications associated with interactions between blood and foreign materials.

Abstract: A medicinal composition and method to treat, minimize, or prevent post-ischemic brain cell deterioration that comprises nitrous oxide or a nitrous oxide donor. The method comprises administering the medicinal composition prior to or subsequent to a stroke.

Abstract: A method is provided for enhancing the solubility of an ionizable compound in a lipophilic medium by admixing the compound with an effective solubility-enhancing amount of an N,N-dinitramide salt. The ionizable compound, upon ionization, gives rise to a biologically active cationic species that ionically associates with the N,N-dinitramide anion N(NO2)2− following admixture with the N,N-dinitramide salt. The biologically active cationic species may be a pharmacologically active cation, in which case the method is useful for enhancing the penetration of the blood-brain barrier by the pharmacologically active cation. In other embodiments, the ionizable compounds are medical imaging or diagnostic agents, or agricultural agents such as pesticides. Salts of biologically active cations and N,N-dinitramide ion are also provided as novel compositions of matter.

Abstract: Application of an alkaline earth metal salt selected from calcium and strontium salts can steadily denature the allergens those exist in the environment without any coloring trouble on the treated material.

Abstract: A water treatment agent and method of treating water to inhibit, reduce, or prevent the formation of algae and bacteria in a water body. The water treatment agent may include copper sulfate penta-hydrate and/or silver, di-sodium ethylene di-amine tetra-acetic acid dihydrate, a scale inhibitor, a shocking agent and a buffer agent. For instance, the treatment agent may include a composition of copper sulfate pentahydrate, di-sodium ethylene di-amine tetra-acetic acid, monopotassium phosphate or sulfuric acid, and potassium monopersulfate and 1-hydroxyethylidene-1,1-diphosphonic acid.

Abstract: The present invention provides a method of administration of an agent which acts to remodel neuronal or vascular pathways for the long term management of sexual dysfunction in both males and females. In a preferred embodiment, the invention provides a method of ameliorating or reversing pathogenic vascular degradative modeling in the ilio-hypogastric-pudendal arterial bed and genitalia comprising administering to a human patient in need of such treatment a therapeutically effective amount of an anti-pressor agent. The anti-pressor agent comprises one or more compounds selected from the therapeutic classes of direct vasodilators such as hydralazine and NO donors, ACE inhibitors, angiotensin-II receptor antagonists, &agr;1-adrenergic receptor antagonists, &bgr;-adrenergic receptor antagonists, calcium channel blockers, and phosphodiesterase inhibitors.

Abstract: Provided are methods and topical pharmaceutical formulations for use in the treatment of warts. The invention involves the topical administration of a pharmacologically active base in a formulation having a pH of about 7.5 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5. These basic formulations can be used to treat human papilloma virus infections, particularly cutaneous warts.

Abstract: A method for lessening or preventing non-pulmonary ischemia-reperfusion injury or inflammation in a mammal by identifying a mammal which has ischemia-reperfusion or is at risk for developing ischemia-reperfusion in a non-pulmonary tissue; and causing the mammal to inhale a therapeutically effective amount of gaseous nitric oxide sufficient to diminish the ability of leukocytes or platelets to become activated in a manner that contributes to an inflammatory process at the site of the ischemia-reperfusion or inflammation in the non-pulmonary tissue, thereby lessening or preventing non-pulmonary ischemia-reperfusion injury in the mammal.

Abstract: A storage and delivery system for directly applying nitric oxide to a user includes a portable and disposable capsule and a source of nitric oxide gas disposed within the cavity. Gas flow control apparatus controls the flow of nitric oxide gas from the cavity. Gas flow initiation apparatus allows the user to initiate the flow of nitric oxide gas. The encapsulated nitric oxide gas is applied by positioning the capsule proximate to the objective site of the user and initiating flow of the nitric oxide gas.

Abstract: A method of treating infected tissue with topical nitric oxide exposure includes the steps of providing a source of nitric oxide containing gas and delivering the nitric oxide containing gas to a skin surface containing infected tissue so as to bathe the infected tissue with nitric oxide.

Abstract: The invention relates to long-acting nitrous acid compositions that disinfect inanimate surfaces and animal tissues, and that can be used to treat diseases and wounds. Compositions of the invention are single-phase, metastable nitrous acid solutions that exhibit enhanced germicidal efficacy and can have an effective lifetime exceeding several years. Compositions of the invention have a wide variety of applications that include, but are not limited to, teat dips, oral rinses, instrument sterilization, and disinfection of food.

Abstract: In the field of treatment of erectile dysfunction there is disclosed a novel therapy in which the actions of an agent or agents, produce a combination of effects to induce effective erection (and avoid priapism) while reducing or entirely avoiding pain. The method taught combines a first action of an agent which is to antagonize a drug-induced pain stimulus within nociceptive nerves of penile tissue with a second action of either the same agent or of a second agent, which enhances, synergistically, smooth muscle relaxation. The synergism allows for at least an equivalent effect of smooth muscle relaxation to be obtained at significantly lower doses of a smooth muscle relaxing agent such as PGE1 which in standard therapy is also in 40-45% of cases pain-inducing at doses which achieve effective erection.

Abstract: Three solution application method for tattoo removal.

Abstract: There is provided a method of increasing insulin sensitivity by administering an effective amount of a compound which stimulates nitric oxide production in the liver. Also provided is a pharmaceutical composition having an effective amount of a compound which stimulates nitric oxide production in the liver and a pharmaceutically acceptable carrier.

Abstract: A unique and synergistic composition is disclosed for cleansing the sinuses to reduce inflammation and improve breathing. The disclosure is also related to a composition for freshening and cleansing the sinus cavities and nostrils that includes a homeopathic ingredient and saline carrier solution. The disclosure is also related to the use of such composition to provide many anticipated and unexpected benefits that emanate from cleansing debris and microbes from the sinuses and nostrils.

Abstract: A method of treating laminitis in a horse is disclosed, comprising administering to the horse a naturally chelated trace mineral composition; promoting healthy skin, hair and hoof tissue. A method of reducing dietary intake is also disclosed, comprising administering to a horse in need thereof, effective amounts of a naturally chelated trace mineral composition. A method of preparing the chelated trace mineral composition from ocean seabed rock is further disclosed, as well as the chelated trace mineral composition.

Abstract: Sexual wellness or sexual fitness is enhanced over time by administrating on a daily basis a source of proanthocyanidins and a source of arginine. Both sources may be blended into a composition or taken separately from a kit. The source of arginine may be a salt or peptide of L-arginine and aspartic acid such as arginine aspartate. The proanthocyanidins stimulate an endothelial NO-synthase enzyme, which serves as a catalyst for synthesis of the nitric oxide from a substration that is the source of the arginine. A sufficient amount of the nitric oxide is released over time to enhance sexual wellness or sexual fitness. In case of low levels of androgenic hormones in both sexes, the combination may contain as a further ingredient a sex hormone or a sex hormone precursor or a sex hormone stimulant or a sex hormone bioavailability enhancer.

Abstract: The present invention relates to the treatment of disorders using nitric oxide (NO), heme oxygenase-1 (HO-1) and heme degradation products such as carbon monoxide (CO), biliverdin, bilirubin and iron.

Abstract: Ectoparasites, such as fleas, ticks, mites and lice, are removed from a human or animal host after applying a composition to the affected area that causes desiccation of the organism. In one embodiment, treatment is effected by applying a substantially anhydrous composition that has a strong affinity for water. As the composition hydrates, it desiccates the pests and facilitates their mechanical removal, such as by combing.

Abstract: A storage and delivery system for directly applying nitric oxide to a user includes a portable and disposable capsule and a source of nitric oxide gas disposed within the cavity. Gas flow control apparatus controls the flow of nitric oxide gas from the cavity. Gas flow initiation apparatus allows the user to initiate the flow of nitric oxide gas. The encapsulated nitric oxide gas is applied by positioning the capsule proximate to the objective site of the user and initiating flow of the nitric oxide gas.

Abstract: The present invention provides methods and compositions for promoting healing of damaged tissue that result in an increased level of nitric oxide in the vicinity of the damaged tissue. Also provided are methods and compositions for inhibiting unwanted wound healing by inhibiting the activity of nitric oxide in the tissue.

Abstract: The present invention provides a dosage form for the treatment of bacterial, viral or fungal conditions which comprises, a pharmaceutically acceptable acidifying agent in an amount sufficient to reduce the pH at an environment of use to below pH4, and a pharmaceutically acceptable source of nitrite ions or a nitrate precursor therefor; wherein said acidifying agent and said source of nitrite ions or nitrate precursor are separately disposed in respective pharmaceutically acceptable carriers for admixture at the intended environment of use to release NO or NO2 ions.

Abstract: A method for lessening or preventing non-pulmonary ischemia-reperfusion injury or inflammation in a mammal by identifying a mammal which has ischemia-reperfusion or is at risk for developing ischemia-reperfusion in a non-pulmonary tissue; and causing the mammal to inhale a therapeutically effective amount of gaseous nitric oxide sufficient to diminish the ability of leukocytes or platelets to become activated in a manner that contributes to an inflammatory process at the site of the ischemia-reperfusion or inflammation in the non-pulmonary tissue, thereby lessening or preventing non-pulmonary ischemia-reperfusion injury in the mammal.

Abstract: The is invention is directed to a composition useful for assisting in supplying a warm-blooded animal with many of its nutritional needs. More specifically, this invention is directed to a composition whereby many of the vitamins, minerals, amino acids and cofactors are suspended in a matrix which when administered to a mammal provides substantial benefit.

Abstract: The present invention provides a dosage form for the treatment of bacterial, viral or fungal conditions which comprises, a pharmaceutically acceptable acidifying agent in an amount sufficient to reduce the pH at an environment of use to below pH4, and a pharmaceutically acceptable source of nitrite ions or a nitrate precursor therefor; wherein said acidifying agent and said source of nitrite ions or nitrate precursor are separately disposed in respective pharmaceutically acceptable carriers for admixture at the intended environment of use to release NO or NO2 ions. The invention also provides delivery systems for the topical medicament.

Abstract: Embodiments of the invention include methods and compositions for the inhibition of Aldose Reductase by nitric oxide. Certain embodiments of the invention include the induction of nitric oxide by administration of a nitric oxide donor, nitric oxide precursor, inhibitor of a nitric oxide synthase inhibitor, and/or an activator of nitric oxide synthase. Methods may include the treatment of various disease states by inhibiting Aldose Reductase.

Abstract: Extremely hydrophobic nitric oxide (NO) releasing polymers are disclosed. The extremely hydrophobic NO-releasing polymers provided are extensively cross-linked polyamine-derivatized divinylbenzene diazeniumdiolates. These polymers can be loaded with extremely high NO levels and designed to release NO in manners than mimic natural biological systems. The NO-releasing extremely hydrophobic polymers provided can maintain a sustained NO release for periods exceeding nine months. Also provided are related medical devices made using these NO-releasing extremely hydrophobic polymers.

Abstract: Three solution application method for tattoo removal.

Abstract: The products of the acidification of nitrite are useful to control multiply drug resistant bacteria, such as methicillin resistant S. aureurs.

Abstract: Use of inhalable gaseous nitric oxide (NO) in combination with a cyclooxygenase inhibitor for the manufacture of a medicament for treating pulmonary vasoconstriction or airway constriction in a mammal, including man, in order to counteract a hypo- or non-response to treatment with gaseous nitric oxide or nitric oxide donor only and/or to counteract a rebound response in the case of withdrawal of treatment with gaseous nitric oxide or nitric oxide donor only said combination being use in a therapeutically effective amount to accomplish relaxation of said pulmonary vasoconstriction or airway constriction. A method and a pharmaceutical preparation for the treatment of pulmonary vasoconstriction or airway constriction while using the above-mentioned combination.

Abstract: A method and composition are provided for the treatment of an anorectal disorder and for controlling the pain associated therewith. The method comprises administering to a subject in need of such treatment therapeutically effective amounts of a calcium channel blocker either alone or together with a nitric oxide donor. Amlodipine, anipamil, barnidipine, benidipine, bepridil, darodipine, diltiazem, efonidipine, felodipine, isradipine, lacidipine, lercanidipine, lidoflazine, manidipine, mepirodipine, nicardipine, nifedipine, niludipine, nilvadipine, nimodipine, nisoldipine, nitrendipine, perhexiline, tiapamil, verapamil and pharmaceutically acceptable salts thereof, are suitable calcium channel blockers.

Abstract: A pharmaceutically delivery system is described comprising a pharmaceutically active agent and acidified nitrite as an agent to produce local production of nitric oxide at the skin surface. The dosage form may be in any pharmaceutically acceptable carrier means and comprises an acidifying agent adapted to reduce the pH at the environment. In one embodiment, a barrier consisting of a membrane allows diffusions of the anaesthetic and nitrite ions while preventing direct contact of the skin and acidifying agent.

Abstract: The present invention provides a method and device for exposing injured mammalian tissues, in a non-abrasive manner, to an effective amount of exogenous gaseous nitric oxide (gNO) in order to promote healing by reducing the size, duration and severity of wounds as well as controlling the infection by reducing number of pathogens at the site and the surrounding area.

Abstract: The invention provides NO— or NO−-releasing imidate, thioimidate, and amide diazeniumdiolates, in which the N2O2− functional group is bonded to a carbon atom. The invention also provides compositions comprising such diazeniumdiolate compounds, and methods of using such compounds and compositions. The invention further provides a method of preparing NO— or NO−-releasing imidate, thioimidate, and amide diazeniumdiolates.

Abstract: A polymeric body covering article that generates and releases gas upon activation by electromagnetic energy and/or moisture. The gas provides antimicrobial and/or antiodor protection to objects in contact or in proximity to the interior surface of the article and/or to objects in contact or in proximity to the exterior surface of the article.

Abstract: This invention provides methods and compositions for using nitric oxide in a photoradiation pathogen inactivation process for whole blood and blood components to improve pathogen kill and to improve preservation of the quality of the blood components. This invention provides methods for using nitric oxide in combination with oxygen, photosensitizers, quencher and/or glycolysis inhibitor, and compositions comprising blood components decontaminated by these methods. Nitric oxide is provided using nitric oxide gas, or nitric oxide generators such as L-arginine, and/or N-acetyl-cysteine. This invention also provides compositions suitable for photoradiation pathogen inactivation that include fluid comprising a blood component, a photosensitizer, and dissolved nitric oxide. This invention provides decontamination systems useful for performing the methods of this invention and methods for making the decontamination systems.

Abstract: Compositions and methods for destroying biological agents such as toxins and bacteria are provided wherein the substance to be destroyed is contacted with finely divided metal oxide or hydroxide nanocrystals. In various embodiments, the metal oxide or metal hydroxide nanocrystals have reactive atoms stabilized on their surfaces, species adsorbed on their surfaces, or are coated with a second metal oxide. The desired metal oxide or metal hydroxide nanocrystals can be pressed into pellets for use when a powder is not feasible. Preferred metal oxides for the methods include MgO, SrO, BaO, CaO, TiO2, ZrO2, FeO, V2O3, V2O5, Mn2O3, Fe2O3, NiO, CuO, Al2O3, SiO2, ZnO, Ag2O, [Ce(NO3)3—Cu(NO3)2]TiO2, Mg(OH)2, Ca(OH)2, Al(OH)3, Sr(OH)2, Ba(OH)2, Fe(OH)3, Cu(OH)3, Ni(OH)2, Co(OH)2, Zn(OH)2, AgOH, and mixtures thereof.

Abstract: The present invention relates to methods and formulations for inhibiting, treating and preventing a malignant cell phenotype, cell, tumor and/or disease. Administration of nitric oxide mimetics, such as low doses, is sufficient to increase, restore or maintain nitric oxide-mediated signaling in cells so that malignant cell phenotypes, cells, tumors and/or diseases are inhibited or prevented. These methods and formulations are particularly useful in treating and preventing cancer in animals.

Abstract: The present invention relates generally to compositions and methods for the use of nitrous acid solutions to disinfect inanimate surfaces and animal tissues, and to treat diseases and wounds. More specifically, the invention deals with the partial and selected conversion of nitrite ion to nitrous acid in order to optimize the germicidal efficacy and duration of the nitrous acid consistent with the nature of the intended application.

Abstract: Compositions and methods for use for treating, pulmonary hypertension, in particular neonatal pulmonary hypertension and early lung inflammation, are described. In a first embodiment, the composition comprises pulmonary vasodilators and mitochondrial targeted antioxidants in mixture with a lung surfactant. Preferably, the composition comprises one or more chemicals selected from the group consisting of a long-acting nitric oxide donors, antioxidants, endothelin-1 receptor antagonists, and antithromboxanes in mixture with a lung surfactant. In a second embodiment, the present invention provides a composition for treating neonatal pulmonary hypertension and early lung inflammation in mammals who do not respond to nitric oxide treatment alone. In this embodiment, the composition comprises liposomes comprising a pulmonary or lung surfactant and which contains vasodilators and chemicals which modulate development of acute inflammation.